Compare Stocks: INMB, CAMP, ALEC, and ALXO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$2.14	$1.93	$1.09 ▼ $3.40	$238.95M	0.65	1.31 million shs	4.70 million shs
ALXO ALX Oncology	$1.94 +2.1%	$2.02	$1.01 ▼ $2.66	$262.73M	0.39	624,569 shs	1.04 million shs
CAMP CAMP4 Therapeutics	$4.25 -2.1%	$4.12	$2.20 ▼ $7.75	$272.35M	0.27	297,092 shs	101,146 shs
INMB INmune Bio	$2.22 -3.9%	$2.06	$1.09 ▼ $2.60	$64.11M	0.93	314,629 shs	228,166 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	0.00%	-13.01%	-0.47%	+39.87%	-24.65%
ALXO ALX Oncology	+2.11%	-3.48%	-3.48%	+22.78%	+65.81%
CAMP CAMP4 Therapeutics	-2.07%	-3.63%	-6.18%	+1.43%	+50.07%
INMB INmune Bio	-3.90%	-9.02%	+8.82%	+79.03%	+26.14%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$2.14	$1.93	$1.09 ▼ $3.40	$238.95M	0.65	1.31 million shs	4.70 million shs
ALXO ALX Oncology	$1.94 +2.1%	$2.02	$1.01 ▼ $2.66	$262.73M	0.39	624,569 shs	1.04 million shs
CAMP CAMP4 Therapeutics	$4.25 -2.1%	$4.12	$2.20 ▼ $7.75	$272.35M	0.27	297,092 shs	101,146 shs
INMB INmune Bio	$2.22 -3.9%	$2.06	$1.09 ▼ $2.60	$64.11M	0.93	314,629 shs	228,166 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	0.00%	-13.01%	-0.47%	+39.87%	-24.65%
ALXO ALX Oncology	+2.11%	-3.48%	-3.48%	+22.78%	+65.81%
CAMP CAMP4 Therapeutics	-2.07%	-3.63%	-6.18%	+1.43%	+50.07%
INMB INmune Bio	-3.90%	-9.02%	+8.82%	+79.03%	+26.14%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALEC Alector	2.13	Hold	$3.63	69.39% Upside
ALXO ALX Oncology	2.67	Moderate Buy	$4.60	137.11% Upside
CAMP CAMP4 Therapeutics	2.67	Moderate Buy	$9.56	125.00% Upside
INMB INmune Bio	2.50	Moderate Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest INMB, CAMP, ALEC, and ALXO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	CAMP CAMP4 Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/19/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	CAMP CAMP4 Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/14/2026	CAMP CAMP4 Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	CAMP CAMP4 Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$15.00
8/14/2026	CAMP CAMP4 Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$12.00 ➝ $15.00
8/13/2026	ALEC Alector	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/5/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/5/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALEC Alector	$13.86M	17.24	N/A	N/A	$0.28 per share	7.64
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$0.48 per share	N/A
CAMP CAMP4 Therapeutics	$4.22M	63.26	N/A	N/A	$1.02 per share	4.17
INMB INmune Bio	N/A	N/A	N/A	N/A	$0.88 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALEC Alector	-$142.93M	-$1.10	N/A	N/A	N/A	-850.13%	-531.03%	-44.00%	11/5/2026 (Estimated)
ALXO ALX Oncology	-$101.69M	-$1.13	N/A	N/A	N/A	N/A	-90.30%	-67.28%	11/6/2026 (Estimated)
CAMP CAMP4 Therapeutics	-$80.40M	-$2.32	N/A	N/A	N/A	-2,543.74%	-252.79%	-85.65%	N/A
INMB INmune Bio	-$45.93M	-$0.67	N/A	N/A	N/A	N/A	-82.87%	-62.23%	10/29/2026 (Estimated)

Latest INMB, CAMP, ALEC, and ALXO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CAMP CAMP4 Therapeutics	-$0.24	-$0.58	-$0.34	-$0.58	N/A	$1.78 million
8/6/2026	Q2 2026	ALEC Alector	-$0.2286	-$0.21	+$0.0186	-$0.21	$1.71 million	$3.32 million
8/6/2026	Q2 2026	ALXO ALX Oncology	-$0.1429	-$0.13	+$0.0129	-$0.13	N/A	N/A
8/6/2026	Q2 2026	INMB INmune Bio	-$0.2067	-$0.05	+$0.1567	-$0.05	$1.16 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALEC Alector	N/A	N/A	N/A	N/A	N/A
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
CAMP CAMP4 Therapeutics	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALEC Alector	0.80	5.26	5.26
ALXO ALX Oncology	0.07	9.71	9.71
CAMP CAMP4 Therapeutics	N/A	4.70	4.70
INMB INmune Bio	N/A	4.04	4.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALEC Alector	85.83%
ALXO ALX Oncology	97.97%
CAMP CAMP4 Therapeutics	N/A
INMB INmune Bio	12.72%

Insider Ownership

Company	Insider Ownership
ALEC Alector	8.30%
ALXO ALX Oncology	12.40%
CAMP CAMP4 Therapeutics	21.69%
INMB INmune Bio	21.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALEC Alector	270	111.66 million	102.39 million	Optionable
ALXO ALX Oncology	40	138.28 million	121.13 million	Optionable
CAMP CAMP4 Therapeutics	644	62.75 million	49.14 million	No Data
INMB INmune Bio	10	27.75 million	21.82 million	Optionable

INMB, CAMP, ALEC, and ALXO Headlines

Recent News About These Companies

INmune Bio to Present at the H.C. Wainwright Global Investment Conference

September 9 at 8:00 AM | globenewswire.com

INmune Bio (NASDAQ:INMB) Stock Price Down 1.3% - What's Next?

August 31, 2026 | marketbeat.com

INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment

August 28, 2026 | seekingalpha.com

INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings

August 26, 2026 | globenewswire.com

INmune Bio targets Ebstrocel U.K. MAA by end of Q3 or early Q4 2026 while outlining $1M-$1.5M monthly burn

August 7, 2026 | seekingalpha.com

INmune Bio (INMB) Q2 2026 Earnings Call Transcript

August 7, 2026 | finance.yahoo.com

INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress

August 6, 2026 | markets.businessinsider.com

INmune Bio Receives R&D Rebates of Approximately $4.6 Million

July 31, 2026 | globenewswire.com

INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th

July 31, 2026 | globenewswire.com

INmune Bio, Inc.: INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom Platform

July 30, 2026 | finanznachrichten.de

INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform

July 30, 2026 | globenewswire.com

INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform

July 20, 2026 | globenewswire.com

INmune Bio Study Finds Soluble TNF Inhibition with XPro1595 Prevents TBI-Driven Amyloid Pathology in Alzheimer’s Model

July 15, 2026 | quiverquant.comQ

INmune Bio's XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study

July 15, 2026 | globenewswire.com

INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC

July 9, 2026 | markets.businessinsider.com

INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer's Disease at AAIC

July 9, 2026 | globenewswire.com

INmune Bio Inc. Common stock (INMB) Insider Activity

July 2, 2026 | nasdaq.com

INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion

July 1, 2026 | globenewswire.com

Analysts Are Bullish on These Healthcare Stocks: Inmune Bio (INMB), AbSci (ABSI)

June 25, 2026 | theglobeandmail.com

INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™

June 25, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

INMB, CAMP, ALEC, and ALXO Company Descriptions

Alector NASDAQ:ALEC

$2.14 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.13 -0.01 (-0.47%)

As of 09/11/2026 07:30 PM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

ALX Oncology NASDAQ:ALXO

$1.94 +0.04 (+2.11%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.94 0.00 (0.00%)

As of 09/11/2026 07:30 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

CAMP4 Therapeutics NASDAQ:CAMP

$4.25 -0.09 (-2.07%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$4.32 +0.07 (+1.65%)

As of 09/11/2026 07:30 PM Eastern

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location. The company also offers telematics products, including asset tracking units, mobile telematics devices, fixed and mobile wireless gateways, and routers; and advanced telematics products for the broader connected vehicle and Internet of Things marketplace, which enable customers to optimize their operations by collecting, monitoring, and reporting business-critical information and desired intelligence from remote and mobile assets. In addition, it offers professional services, including project management, engineering services, and installation services. The company sells its products and services to customers in the automotive, telecommunications, industrial equipment, transportation and logistics, government and municipalities, insurance, original equipment manufacturers, and leasing companies. It markets through direct sales organization, channel partner program, original equipment manufacturers, and independent sales representatives and distributors, as well as its websites and digital platform. The company was incorporated in 1981 and is headquartered in Irvine, California.

INmune Bio NASDAQ:INMB

$2.22 -0.09 (-3.90%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.22 -0.01 (-0.23%)

As of 09/11/2026 07:30 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INMB, CAMP, ALEC, and ALXO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INMB, CAMP, ALEC, and ALXO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INMB, CAMP, ALEC, and ALXO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INMB, CAMP, ALEC, and ALXO Company Descriptions

Alector NASDAQ:ALEC

ALX Oncology NASDAQ:ALXO

CAMP4 Therapeutics NASDAQ:CAMP

INmune Bio NASDAQ:INMB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INMB, CAMP, ALEC, and ALXO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INMB, CAMP, ALEC, and ALXO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INMB, CAMP, ALEC, and ALXO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INMB, CAMP, ALEC, and ALXO Company Descriptions

Alector NASDAQ:ALEC

ALX Oncology NASDAQ:ALXO

CAMP4 Therapeutics NASDAQ:CAMP

INmune Bio NASDAQ:INMB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools